Blocking pro-invasive signaling and inflammatory activation in triple-negative breast cancer with nucleic-acid scavengers (NASs). This is an ASCO Meeting Abstract from the 2020 ASCO Annual Meeting I.

Agilent Technologies Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved its Dako PD-L1 IHC 22C3 pharmDx assay for expanded use in urothelial carcinoma. The assay is now ...

Correlation of β-catenin expression in non-small cell lung cancer to prognosis and CD8 positive cells infiltration. This is an ASCO Meeting Abstract from the 2018 ASCO-SITC Clinical Immuno-Oncology ...

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that its PD-L1 IHC 22C3 pharmDx assay is now labelled for use in TNBC in the European Union. PD-L1 expression ...

Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, today announced that it will provide clinical laboratory testing using the PD-L1 IHC 22C3 PharmDx™ ...

CARPINTERIA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that its Dako PD-L1 IHC 22C3 pharmDx now has an expanded label approved by the U.S. Food and Drug ...

Announcement marks the seventh cancer type for which PD-L1 IHC 22C3 pharmDx has gained approval in the US SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (NYSE: A) today announced it ...

Patients with gastric or GEJ adenocarcinoma whose tumors express PD-L1 can now be identified for potential treatment with KEYTRUDA® (pembrolizumab) using PD-L1 IHC 22C3 pharmDx (SK006) SANTA CLARA, ...

Agilent Technologies A has bolstered presence in the clinical and diagnostic testing market of Europe by expanding the use of PD-L1 IHC 22C3 pharmDx assay in patients suffering from esophageal cancer ...

Agilent Technologies Inc. announced that the company’s PD-L1 IHC 22C3 pharmDx assay has expanded its use in Europe. The assay is now CE-IVD marked for use as an aid in identifying esophageal cancer ...